CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Helius Medical Technologies, Inc. - HSDT CFD

8.7196
9.55%
Market Trading Hours* (UTC) Opens on Thursday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.2408
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.02
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Helius Medical Technologies Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 7.9596
Open* 7.8396
1-Year Change* 2384.03%
Day's Range* 7.8396 - 8.7296
52 wk Range 5.69-29.50
Average Volume (10 days) 2.19M
Average Volume (3 months) 7.67M
Market Cap 4.55M
P/E Ratio -100.00K
Shares Outstanding 565.97K
Revenue 787.00K
EPS -120.55
Dividend (Yield %) N/A
Beta 1.26
Next Earnings Date Nov 13, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 26, 2023 7.9596 0.3100 4.05% 7.6496 7.9996 7.6496
Sep 25, 2023 7.6396 -0.5100 -6.26% 8.1496 8.2896 7.5496
Sep 22, 2023 8.1796 -0.3000 -3.54% 8.4796 10.8996 8.1796
Sep 21, 2023 8.5696 -0.1300 -1.49% 8.6996 8.8896 8.3996
Sep 20, 2023 8.4496 0.2000 2.42% 8.2496 8.8396 8.2496
Sep 19, 2023 8.4596 -0.2400 -2.76% 8.6996 8.8796 8.1596
Sep 18, 2023 8.7196 0.4200 5.06% 8.2996 8.7596 8.2996
Sep 15, 2023 8.2996 0.0500 0.61% 8.2496 8.4496 7.9996
Sep 14, 2023 8.5096 0.3100 3.78% 8.1996 8.7496 8.1996
Sep 13, 2023 8.3496 0.3500 4.38% 7.9996 8.4496 7.9996
Sep 12, 2023 8.2696 -0.5200 -5.92% 8.7896 8.7896 8.1096
Sep 11, 2023 8.9996 -0.8000 -8.16% 9.7996 10.3496 8.6196
Sep 8, 2023 9.4330 1.5900 20.27% 7.8430 10.9230 7.8430
Sep 7, 2023 7.8530 -0.1400 -1.75% 7.9930 8.6230 7.5030
Sep 6, 2023 8.8930 -0.2800 -3.05% 9.1730 9.3630 7.5930
Sep 5, 2023 9.8930 -2.2800 -18.73% 12.1730 12.5830 9.6030
Sep 1, 2023 7.3630 1.0700 17.00% 6.2930 7.8730 6.2830
Aug 31, 2023 6.7730 -0.3600 -5.05% 7.1330 8.6430 6.6730
Aug 30, 2023 7.7230 1.2500 19.31% 6.4730 7.8930 6.2130
Aug 29, 2023 7.1730 0.6800 10.47% 6.4930 7.2930 6.4930

Helius Medical Technologies, Inc. Events

Time (UTC) Country Event
Monday, November 13, 2023

Time (UTC)

13:30

Country

US

Event

Q3 2023 Helius Medical Technologies Inc Earnings Release
Q3 2023 Helius Medical Technologies Inc Earnings Release

Forecast

-

Previous

-
Thursday, March 7, 2024

Time (UTC)

10:59

Country

US

Event

Q4 2023 Helius Medical Technologies Inc Earnings Release
Q4 2023 Helius Medical Technologies Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0.787 0.522 0.661 1.496 0.478
Total Operating Expense 16.303 18.664 15.047 25.492 27.153
Selling/General/Admin. Expenses, Total 10.64 12.158 9.404 16.521 17.214
Research & Development 4.262 5.99 4.582 8.061 9.939
Operating Income -15.516 -18.142 -14.386 -23.996 -26.675
Interest Income (Expense), Net Non-Operating 1.437 0.01 0.193 14.12 -2.011
Other, Net 0.007 0 0.063 0.095 0.063
Net Income Before Taxes -14.072 -18.132 -14.13 -9.781 -28.623
Net Income After Taxes -14.072 -18.132 -14.13 -9.781 -28.623
Net Income Before Extra. Items -14.072 -18.132 -14.13 -9.781 -28.623
Net Income -14.072 -18.132 -14.13 -9.781 -28.623
Income Available to Common Excl. Extra. Items -14.072 -18.132 -14.13 -9.781 -28.623
Income Available to Common Incl. Extra. Items -14.072 -18.132 -14.13 -9.781 -28.623
Diluted Net Income -14.072 -18.132 -14.13 -9.781 -28.623
Diluted Weighted Average Shares 0.26994 0.04914 0.02396 0.01506 0.01302
Diluted EPS Excluding Extraordinary Items -52.1295 -369.019 -589.844 -649.559 -2198.38
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -49.3252 -368.653 -576.904 -649.559 -2198.38
Total Extraordinary Items
Revenue 0.787 0.522 0.661 1.496 0.478
Cost of Revenue, Total 0.463 0.298 0.388 0.846 0
Gross Profit 0.324 0.224 0.273 0.65 0.478
Depreciation / Amortization 0.181 0.2 0.363 0.064 0
Dilution Adjustment 0
Unusual Expense (Income) 0.757 0.018 0.31
Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
Total revenue 0.282 0.196 0.119 0.19 0.258
Revenue 0.282 0.196 0.119 0.19 0.258
Cost of Revenue, Total 0.15 0.101 0.088 0.124 0.129
Gross Profit 0.132 0.095 0.031 0.066 0.129
Total Operating Expense 2.951 5.049 3.549 4.754 4.36
Selling/General/Admin. Expenses, Total 1.967 3.393 2.461 2.819 2.376
Research & Development 0.794 0.751 0.953 1.764 1.808
Depreciation / Amortization 0.04 0.047 0.047 0.047 0.047
Operating Income -2.669 -4.853 -3.43 -4.564 -4.102
Interest Income (Expense), Net Non-Operating -2.223 3.823 -0.38 0.217 0
Other, Net 0.006 0 0 0.001 0
Net Income Before Taxes -4.886 -1.03 -3.81 -4.346 -4.102
Net Income After Taxes -4.886 -1.03 -3.81 -4.346 -4.102
Net Income Before Extra. Items -4.886 -1.03 -3.81 -4.346 -4.102
Net Income -4.886 -1.03 -3.81 -4.346 -4.102
Income Available to Common Excl. Extra. Items -4.886 -1.03 -3.81 -4.346 -4.102
Income Available to Common Incl. Extra. Items -4.886 -1.03 -3.81 -4.346 -4.102
Diluted Net Income -4.886 -1.03 -3.81 -4.346 -4.102
Diluted Weighted Average Shares 0.56394 0.17087 0.07857 3.78787 3.13886
Diluted EPS Excluding Extraordinary Items -8.66398 -6.02811 -48.4893 -1.14735 -1.30684
Diluted Normalized EPS -8.66398 -1.59774 -48.4893 -1.14735 -1.30684
Dividends per Share - Common Stock Primary Issue 0 0 0
Unusual Expense (Income) 0 0.757
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 16.697 12.594 4.685 7.241 26.961
Cash and Short Term Investments 14.549 11.005 3.331 5.459 25.583
Cash 14.549 11.005 3.331 5.459 25.583
Total Receivables, Net 0.343 0.251 0.23 0.574 0.275
Accounts Receivable - Trade, Net 0.071 0.066 0.074 0.21 0.275
Prepaid Expenses 1.216 0.862 0.735 0.61 0.447
Total Assets 17.287 14.102 6.547 10.347 27.827
Total Current Liabilities 1.988 2.653 2.424 3.802 17.973
Payable/Accrued
Notes Payable/Short Term Debt 0 0 0 0
Other Current Liabilities, Total 0.027 0.148 0.281 0.435 13.769
Total Liabilities 9.136 2.846 2.676 4.512 17.973
Total Long Term Debt 0 0 0 0
Total Equity 8.151 11.256 3.871 5.835 9.854
Common Stock 0.028 0.004 0.001 0.031 0.026
Additional Paid-In Capital 159.618 149.412 123.872 111.479 105.411
Retained Earnings (Accumulated Deficit) -151.107 -137.035 -118.903 -104.773 -94.992
Other Equity, Total -0.388 -1.125 -1.099 -0.902 -0.591
Total Liabilities & Shareholders’ Equity 17.287 14.102 6.547 10.347 27.827
Total Common Shares Outstanding 28.2073 3.78067 1.48436 0.87763 0.7379
Property/Plant/Equipment, Total - Net 0.45 0.412 0.576 1.264 0.554
Property/Plant/Equipment, Total - Gross 0.653 0.779 1.449 0.63
Accumulated Depreciation, Total -0.241 -0.203 -0.185 -0.076
Other Long Term Assets, Total 0 0.018 0.018
Accounts Payable 0.627 1.069 0.747 1.676 2.392
Accrued Expenses 1.334 1.436 1.396 1.691 1.812
Total Inventory 0.589 0.476 0.389 0.598 0.392
Other Current Assets, Total 0 0.264
Note Receivable - Long Term 0 0.294
Other Liabilities, Total 7.148 0.193 0.252 0.71 0
Goodwill, Net 0 0.763 0.759 1.242
Intangibles, Net 0.14 0.333 0.527 0.582
Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
Total Current Assets 16.697 18.217 5.064 8.026 12.594
Cash and Short Term Investments 14.549 16.658 3.273 6.31 11.005
Cash 14.549 16.658 3.273 6.31 11.005
Total Receivables, Net 0.343 0.217 0.196 0.245 0.251
Accounts Receivable - Trade, Net 0.071 0.021 0.009 0.06 0.066
Total Inventory 0.589 0.609 0.577 0.52 0.476
Prepaid Expenses 1.216 0.733 0.996 0.951 0.862
Total Assets 17.287 18.859 6.546 9.618 14.102
Property/Plant/Equipment, Total - Net 0.45 0.464 0.493 0.52 0.412
Goodwill, Net 0 0.753 0.777 0.763
Intangibles, Net 0.14 0.178 0.236 0.291 0.333
Other Long Term Assets, Total 0.004
Total Current Liabilities 1.988 1.2 1.777 2.199 2.653
Accounts Payable 0.627 0.57 1.043 1.111 1.069
Accrued Expenses 1.334 0.604 0.706 1.059 1.436
Other Current Liabilities, Total 0.027 0.026 0.028 0.029 0.148
Total Liabilities 9.136 5.898 2.044 2.488 2.846
Other Liabilities, Total 7.148 4.698 0.267 0.289 0.193
Total Equity 8.151 12.961 4.502 7.13 11.256
Preferred Stock - Non Redeemable, Net
Common Stock 0.028 0.028 0.004 0.004 0.004
Additional Paid-In Capital 159.618 159.386 150.665 149.834 149.412
Retained Earnings (Accumulated Deficit) -151.107 -146.221 -145.191 -141.381 -137.035
Other Equity, Total -0.388 -0.232 -0.976 -1.327 -1.125
Total Liabilities & Shareholders’ Equity 17.287 18.859 6.546 9.618 14.102
Total Common Shares Outstanding 28.2073 28.2013 4.19511 3.7948 3.78067
Property/Plant/Equipment, Total - Gross 0.786 0.653
Accumulated Depreciation, Total -0.266 -0.241
Notes Payable/Short Term Debt 0 0 0 0
Total Long Term Debt 0 0 0 0
Other Current Assets, Total 0.022
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -18.132 -14.13 -9.781 -28.623
Cash From Operating Activities -13.388 -11.738 -20.999 -19.621
Non-Cash Items 4.305 2.926 -9.132 9.961
Changes in Working Capital 0.127 -1.016 -2.277 -1.018
Cash From Investing Activities -0.056 -0.009 -0.769 -0.44
Other Investing Cash Flow Items, Total 0 0.061 -0.416
Cash From Financing Activities 21.126 9.638 1.653 40.028
Financing Cash Flow Items -2.889 -1.015 -0.247 -3.161
Issuance (Retirement) of Stock, Net 24.015 10.653 1.9 43.189
Foreign Exchange Effects -0.008 -0.019 -0.009 0.054
Net Change in Cash 7.674 -2.128 -20.124 20.021
Cash From Operating Activities 0.112 0.119 0.127 0.059
Cash Taxes Paid 0 0
Cash Interest Paid 0 0
Capital Expenditures -0.056 -0.07 -0.353 -0.44
Amortization 0.2 0.363 0.064
Issuance (Retirement) of Debt, Net 0 0
Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
Net income/Starting Line -9.186 -8.156 -4.346 -18.132
Cash From Operating Activities -12.167 -8.346 -4.682 -13.388
Cash From Operating Activities 0.074 0.05 0.025 0.112
Amortization 0.141 0.094 0.047 0.2
Non-Cash Items -1.768 0.765 0.195 4.305
Changes in Working Capital -1.428 -1.099 -0.603 0.127
Cash From Investing Activities -0.013 -0.006 0.004 -0.056
Capital Expenditures -0.019 -0.012 -0.002 -0.056
Cash From Financing Activities 17.869 0.62 -0.017 21.126
Financing Cash Flow Items -0.775 -0.024 -0.017 -2.889
Issuance (Retirement) of Stock, Net 18.644 0.644 0 24.015
Foreign Exchange Effects -0.006 -0.008
Net Change in Cash 5.683 -7.732 -4.695 7.674
Other Investing Cash Flow Items, Total 0.006 0.006 0.006 0
Issuance (Retirement) of Debt, Net 0
Cash Interest Paid 0.927

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Helius Medical Technologies, Inc. Company profile

About Helius Medical Technologies Inc

Helius Medical Technologies, Inc. is a neurotech company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The Company's product, Portable Neuromodulation Stimulator (PoNS) is a class II, non-implantable medical device intended for use as a short-term treatment (14 weeks) of gait deficit due to symptoms from multiple sclerosis (MS), and balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with supervised therapeutic exercise (PoNS Treatment). The Company's subsidiaries include Helius Medical, Inc., Helius Medical Technologies (Canada), Inc., Helius NeuroRehab, Inc., Helius Canada Acquisition Ltd. and Heuro Canada, Inc.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Helius Medical Technologies Inc revenues decreased 21% to $522K. Net loss increased 28% to $18.1M. Revenues reflect Product sales decrease of 21% to $493K, Fee revenue decrease from $9K to $0K. Higher net loss reflects General and administrative increase of 25% to $12.2M (expense), Research and development increase of 31% to $6M (expense), Foreign exchange gain decrease of 95% to $10K (income).

Industry: Advanced Medical Equipment & Technology (NEC)

642 Newtown Yardley Road
NEWTOWN
PENNSYLVANIA 18940
US

Income Statement

  • Annual
  • Quarterly

News

How to Trade The Triple Top

Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

14:13, 27 September 2023
USA flag on the background of stock charts. Financial system in USA

Q4 lookahead: US indices starting to show signs of trouble?

US indices start to draw attention as traders focus on the outlook for Q4.

07:20, 27 September 2023

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

People also watch

ETH/USD

1,596.14 Price
+0.480% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

BTC/USD

26,288.45 Price
+0.400% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

Oil - Crude

93.05 Price
+3.250% 1D Chg, %
Long position overnight fee 0.0588%
Short position overnight fee -0.0807%
Overnight fee time 21:00 (UTC)
Spread 0.030

XRP/USD

0.51 Price
-0.160% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading